- Went public, Jul 2013
- Acquired Immunorizon for $100M, Feb 2023
- Acquired FameWave, Jan 2019
About
Purple Biotech is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219, CM24 and IM1240.
*NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. In a Phase 1/2 study of NT219, the Company is currently advancing it as a monotherapy treatment of solid tumors, and in a dose escalation in combination with cetuximab for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) or colorectal adenocarcinoma (CRC). These studies will be followed by an expansion phase of NT219 at its recommended Phase 2 level in combination with cetuximab in patients with recurrent and metastatic SCCHN.
*CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.
*IM1240 is a preclinical, conditionally-activated tri-specific antibody that engages both T cells and NK cells to mount a strong, localized immune response within the tumor microenvironment. The third arm specifically targets the Tumor Associated Antigen (TAA) 5T4 that is expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness and poor clinical outcomes. IM1240 has a cleavable capping technology that confines the compound’s therapeutic activity to the local tumor microenvironment, and thereby potentially increases the anticipated therapeutic window in patients.
Funding history · 8 rounds · $94.6M total
Q&A
- What is Purple Biotech's primary focus?
- Purple Biotech is a clinical-stage company developing first-in-class therapies to overcome tumor immune evasion and drug resistance.
- When was Purple Biotech founded?
- Purple Biotech was founded in August 1968.
- What is the employee count for Purple Biotech?
- Purple Biotech has 11-50 employees.
- What is the status of Purple Biotech's CM24 therapy?
- CM24 is a humanized monoclonal antibody that blocks CEACAM1. Purple Biotech is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC).
- Has Purple Biotech entered into any clinical collaboration agreements for CM24?
- Yes, Purple Biotech has a clinical collaboration agreement with Bristol Myers Squibb for Phase 2 clinical trials to evaluate CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy.
- What is the most recent funding round Purple Biotech secured?
- Purple Biotech secured a private funding round of $2,800,000 in December 2024.
- Which company did Purple Biotech acquire in February 2023?
- Purple Biotech acquired Immunorizon in February 2023 for $100,000,000.
- When did Purple Biotech last raise capital from Armistice Capital?
- Purple Biotech raised $1,240,000 in a private round in September 2024, with Armistice Capital as a lead investor.
- What is the status of Purple Biotech's NT219 therapy?
- NT219 is a dual inhibitor small molecule targeting IRS1/2 and STAT3. Purple Biotech is currently advancing it as a monotherapy treatment of solid tumors in a Phase 1/2 study, and in combination with cetuximab for recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) or colorectal adenocarcinoma (CRC).
- What is Purple Biotech's total funding raised to date?
- Purple Biotech has raised a total of $94,600,000.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | purple-biotech.com/ |
|---|---|
| linkedin.com/company/6758085 |
Identifiers & details
| Former names | Kitov Pharmaceuticals |
|---|---|
| Founded | 1968-8 |
| Employees (exact) | 11 |
| Market cap | $6.8M |
| Status reason | Public on TASE on Jul, 2013;Public on NASDAQ on Nov, 2015; |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Immunorizon | 2023-02 | $100.0M |
| FameWave | 2019-01 | |
| TyrNovo | 2017-01 | $3.8M |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2025-09 | $3.1M | |||
| 2015-11 | $13.0M | |||
| 2013-07 | $10.0M |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | purple-biotech.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|